Scientific EXPERT Act of 2025 establishes externally led, science-focused drug development meetings for rare diseases.
The Scientific EXPERT Act of 2025 amends the Federal Food, Drug, and Cosmetic Act to create a process for externally led, science-focused drug development meetings. These meetings, convened by the Reagan-Udall Foundation for the Food and Drug Administration, aim to discuss challenges in developing drugs for rare diseases. The Foundation will consult with the Food and Drug Administration, a multistakeholder steering committee, and various stakeholders to plan these meetings.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.